Literature DB >> 25403448

Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics.

James A Balogun1, Eric Monsalves, Kyle Juraschka, Kashif Parvez, Walter Kucharczyk, Ozgur Mete, Fred Gentili, Gelareh Zadeh.   

Abstract

The aim of the study was to establish if the null cell adenoma (NCA) forms a distinct subgroup with unique clinicopathological characteristics within the nonfunctioning pituitary adenoma group particularly in relation to the silent gonadotroph adenomas (SGAs). We identified 31 patients with the pathological diagnosis of NCA verified by routine histology and immunohistochemistry with distinct differentiation from SGAs by an established negative testing for SF-1 at the Toronto Western Hospital between December 2004 and August 2010. We reviewed their demographic data, clinical features, magnetic resonance imaging, and the histologic variables: MIB-1, FGFR4, and P27. We compared these to 63 SGAs identified within the same period. All the NCAs were macroadenomas with diameter ranging from 15-57 mm and tumor volumes between 1.95-53.5 mm(3). Preoperative cavernous sinus tumor growth was able to predict the presence of a residual after surgery (p = 0.023). Furthermore, preoperative cavernous sinus extension (p = 0.002) and negative P27 expression (p = 0.035) were able to independently predict the subsequent growth of the postoperative tumor residual. Comparing the NCA to SGA, we found that MIB-1 was higher in NCA (mean ± SD = 3.43 ± 2.76 %) compared to SGAs (mean ± SD = 2.49 ± 1.41 %) (p = 0.044). The preoperative and postoperative tumor volume doubling times (TVDTs) displayed a negative correlation in the SGA (r = -0.855, p = 0.002) while in the NCA, a positive correlation was evident (r = 0.718, p = 0.029). Our study suggests that the NCAs are a distinct group with differing behavioral characteristics from the SGAs. It also appears that the finding of cavernous sinus extension on preoperative imaging and a negative P27 expression on immunohistochemistry in NCAs may be valuable tools in predicting residual tumor growth which may impact on postoperative care.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25403448     DOI: 10.1007/s12022-014-9347-2

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  40 in total

1.  Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results.

Authors:  M Losa; A Franzin; F Mangili; M R Terreni; R Barzaghi; F Veglia; P Mortini; M Giovanelli
Journal:  Neurosurgery       Date:  2000-12       Impact factor: 4.654

2.  Immunohistochemical analyses of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas.

Authors:  H Nakabayashi; I Sunada; M Hara
Journal:  J Histochem Cytochem       Date:  2001-09       Impact factor: 2.479

Review 3.  The pathogenesis of pituitary tumors.

Authors:  Sylvia L Asa; Shereen Ezzat
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

4.  Nonfunctioning pituitary adenomas: association of Ki-67 and HMGA-1 labeling indices with residual tumor growth.

Authors:  Andrej Šteňo; Jozef Bocko; Boris Rychlý; Martin Chorváth; Peter Celec; Martin Fabian; Víťazoslav Belan; Juraj Šteňo
Journal:  Acta Neurochir (Wien)       Date:  2014-01-23       Impact factor: 2.216

5.  A prospective study of nonfunctioning pituitary adenomas: presentation, management, and clinical outcome.

Authors:  Lukui Chen; William L White; Robert F Spetzler; Bainan Xu
Journal:  J Neurooncol       Date:  2010-08-21       Impact factor: 4.130

6.  Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study.

Authors:  Claudia Ramírez; Sonia Cheng; Guadalupe Vargas; Sylvia L Asa; Shereen Ezzat; Baldomero González; Lourdes Cabrera; Gerardo Guinto; Moisés Mercado
Journal:  J Clin Endocrinol Metab       Date:  2012-03-14       Impact factor: 5.958

7.  Management of large aggressive nonfunctional pituitary tumors: experimental medical options when surgery and radiation fail.

Authors:  Brandon A Miller; W Caleb Rutledge; Adriana G Ioachimescu; Nelson M Oyesiku
Journal:  Neurosurg Clin N Am       Date:  2012-10       Impact factor: 2.509

8.  Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth.

Authors:  Y Greenman; G Ouaknine; I Veshchev; I I Reider-Groswasser; Y Segev; N Stern
Journal:  Clin Endocrinol (Oxf)       Date:  2003-06       Impact factor: 3.478

Review 9.  Practical pituitary pathology: what does the pathologist need to know?

Authors:  Sylvia L Asa
Journal:  Arch Pathol Lab Med       Date:  2008-08       Impact factor: 5.534

10.  A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas.

Authors:  Shozo Yamada; Kenichi Ohyama; Manabu Taguchi; Akira Takeshita; Koji Morita; Koji Takano; Toshiaki Sano
Journal:  Neurosurgery       Date:  2007-09       Impact factor: 4.654

View more
  17 in total

Review 1.  Advances and controversies in the classification and grading of pituitary tumors.

Authors:  E R Laws; D L Penn; C S Repetti
Journal:  J Endocrinol Invest       Date:  2018-06-01       Impact factor: 4.256

2.  [The 2017 WHO classification of pituitary tumors].

Authors:  Wolfgang Saeger
Journal:  Pathologe       Date:  2021-04-20       Impact factor: 1.011

3.  Non-invasive radiomics approach potentially predicts non-functioning pituitary adenomas subtypes before surgery.

Authors:  Shuaitong Zhang; Guidong Song; Yali Zang; Jian Jia; Chao Wang; Chuzhong Li; Jie Tian; Di Dong; Yazhuo Zhang
Journal:  Eur Radiol       Date:  2018-03-23       Impact factor: 5.315

4.  Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers.

Authors:  Joao Paulo Almeida; Corbin C Stephens; Jennifer M Eschbacher; Michelle M Felicella; Kevin C J Yuen; William L White; Michael A Mooney; Anne Laure Bernat; Ozgur Mete; Gelareh Zadeh; Fred Gentili; Andrew S Little
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

5.  Early postoperative growth in non-functioning pituitary adenomas; A tool to tailor safe follow-up.

Authors:  Kristin Astrid Øystese; Manuela Zucknick; Olivera Casar-Borota; Geir Ringstad; Jens Bollerslev
Journal:  Endocrine       Date:  2017-05-17       Impact factor: 3.633

6.  Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas.

Authors:  Ozgur Mete; Karen Gomez-Hernandez; Walter Kucharczyk; Rowena Ridout; Gelareh Zadeh; Fred Gentili; Shereen Ezzat; Sylvia L Asa
Journal:  Mod Pathol       Date:  2016-01-08       Impact factor: 7.842

Review 7.  Non-functioning pituitary adenomas: growth and aggressiveness.

Authors:  Kristin Astrid Øystese; Johan Arild Evang; Jens Bollerslev
Journal:  Endocrine       Date:  2016-04-11       Impact factor: 3.633

8.  Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas.

Authors:  Julieann C Lee; Melike Pekmezci; Jonathan L Lavezo; Hannes Vogel; Laurence Katznelson; Merav Fraenkel; Griffith Harsh; Mohanpal Dulai; Arie Perry; Tarik Tihan
Journal:  Endocr Pathol       Date:  2017-12       Impact factor: 3.943

Review 9.  Overview of the 2017 WHO Classification of Pituitary Tumors.

Authors:  Ozgur Mete; M Beatriz Lopes
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

Review 10.  Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification.

Authors:  Ashley B Grossman; Shereen Ezzat; Sylvia L Asa; Ozgur Mete; Michael D Cusimano; Ian E McCutcheon; Arie Perry; Shozo Yamada; Hiroshi Nishioka; Olivera Casar-Borota; Silvia Uccella; Stefano La Rosa
Journal:  Mod Pathol       Date:  2021-05-21       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.